Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2016-11-16 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-11-16 English
FORM 4 SUBMISSION
Director's Dealing
2016-11-16 English
FORM 4 SUBMISSION
Director's Dealing
2016-11-16 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 14, 2016, by Novavax, Inc. It reports on Item 5.02, which concerns the departure, election, or appointment of directors or certain officers and compensatory arrangements of certain officers. The content details the approval of a form of incentive stock option agreement and a retention plan involving stock options for named executive officers. There is no financial statement or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of management compensation arrangements and changes related to executive officers. Therefore, it fits the category of Board/Management Information (MANG). The document length (7240 characters) and content confirm it is not a mere announcement of a report but a substantive filing about management changes and compensation.
2016-11-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and references a press release and an investor presentation attached as exhibits. The press release announces financial results for the quarter ended September 30, 2016, and the investor presentation is also included. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of these materials. The document length is 4340 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, since this document announces the financial results and references attached exhibits (press release and investor presentation) without containing the full financial data itself, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements. The presence of an investor presentation as an exhibit does not change the classification of the 8-K filing itself. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2016-11-14 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-11-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.